We offer next-generation sequencing and comprehensive fluorescence in situ hybridization (FISH) panels, as well as extensive immunohistochemistry (IHC) offerings, to diagnose and monitor T-cell lymphoma.
Learn about our comprehensive MayoComplete solid tumor panel, which analyzes 515 genes for mutations, rearrangements, and amplifications.
Lung Cancer NGS Panel - Mayo Clinic Laboratories
Our targeted lung cancer panel assesses for mutations in eight genes, and rearrangements in four genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.
Browse our menu of MayoComplete next-generation sequencing assays which are designed to identify a growing list of hematological cancers.
Find out how our streamlined approach to fluorescence in situ hybridization testing can simplify the ordering process and better meet patient needs.
Thrombotic microangiopathy (TMA) - Insights
View our comprehensive testing suite designed to confirm diagnosis and facilitate treatment of thrombotic microangiopathy.
Learn how our melanoma testing identifies variants in 17 genes associated with diagnosis, prognosis, and treatment guidance.
Chromosomal microarray - Insights
Learn how our microarray evaluations identify, analyze, and assess clinically significant chromosomal abnormalities.
Hereditary epilepsy - Insights
Find out how we perform in-depth mutation and copy number variant analysis to determine causes of epilepsy and identify potential treatment options.
This featured section focuses on events, updates, and items of interest for Mayo Clinic Laboratories’ clients, health care providers, lab staff, and the public.